Modality
Gene Therapy
MOA
Cl18.2
Target
TIGIT
Pathway
Tau
Ovarian CaCSU
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Jan 2031
Phase 1Current
NCT04933523
258 pts·Ovarian Ca
2024-06→2028-12·Terminated
NCT06705964
1,045 pts·Ovarian Ca
2024-08→2031-01·Completed
1,303 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-12-062.7y awayPh2 Data· Ovarian Ca
2031-01-034.8y awayPh2 Data· Ovarian Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
P1/2
Termina…
P1/2
Complet…
Catalysts
Ph2 Data
2028-12-06 · 2.7y away
Ovarian Ca
Ph2 Data
2031-01-03 · 4.8y away
Ovarian Ca
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04933523 | Phase 1/2 | Ovarian Ca | Terminated | 258 | DOR |
| NCT06705964 | Phase 1/2 | Ovarian Ca | Completed | 1045 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |